Table 5.
ICU characteristics survival.
| Survivors | Range | Non-survivors | Range | p | |
|---|---|---|---|---|---|
| n | 90 | 94 | |||
| Intubated at ICU admission | 30 (33.3%) | 21 (22.3%) | |||
| ARDS mild at ICU admission | 7 (7.8%) | 7 (7.4%) | |||
| ARDS moderate at ICU admission | 41 (45.6%) | 44 (46.8%) | |||
| ARDS severe at ICU admission | 39 (43.3%) | 43 (45.7%) | |||
| Septic shock at ICU admission | 6 (6.7%) | 18 (19.4%) | < 0.05 | ||
| First Horovitz-index at ICU | 112.5 (83; 165) | 52.5–450 | 105 (75; 142.5) | 45–262.5 | |
| Lowest Horovitz-index at ICU | 75 (52.5; 90) | 22.5–225 | 52.5 (45; 67.5) | 22.5–135 | |
| Pmean at admission [mbar] | 19 (16; 22) | 7–28 | 20 (18; 22) | 8–30 | |
| PEEP at admission [mbar] | 13 (12; 15) | 6–20 | 14 (12; 15) | 6–20 | |
| pH at admission | 7.40 (7.36; 7.46) | 7.17–7.62 | 7.37 (7.31; 7.42) | 6.81–7.59 | |
| PaCO2 at admission [kPa] | 6.29 (5.38; 6.82) | 3.23–9.86 | 6.64 (5.83; 7.52) | 4.42–15.90 | |
| SpO2 at admission [%] | 94 (91; 96) | 56–100 | 93 (89; 96) | 64–100 | |
| SOFA score at ICU admission | 11 (8; 13) | 5–16 | 12 (11; 14) | 4–19 | < 0.05 |
| D-dimers at ICU admission [ng/ml] | 4000 (1808; 7638) | 484–20,000 | 6128 (4114; 10,994) | 495–20,000 | < 0.05 |
| Lactate at ICU admission [mmol/L] | 1.10 (0.85; 1.40) | 0.40–3.30 | 1.30 (0.90; 1.90) | 0.50–9.90 | < 0.05 |
| Duration mechanical ventilation ICU [days] | 10 (6; 17) | 2–56 | 13 (8; 17) | 1–61 | |
| Reintubation | 2 (2.2%) | 2 (2.1%) | |||
| Prone position | 48 (53.3%) | 65 (69.1%) | < 0.05 | ||
| Cycles of prone position | 3 (2; 4) | 1–14 | 4 (3; 7) | 1–11 | < 0.05 |
| Tracheostomy | 41 (45.6%) | 41 (43.6%) | |||
| Days from intubation to Tracheostomy | 13 (10; 15) | 3–26 | 11 (8; 15 | 3–21 | |
| CRRT | 15 (16.7%) | 52 (55.3%) | < 0.05 | ||
| Duration CRRT [hours} | 337.01 (100.66; 483.67) | 17.33–788.74 | 138.10 (30.17; 239.08) | 1.44–906.53 | < 0.05 |
| ECMO | 14 (15.6%) | 35 (37.2%) | < 0.05 | ||
| Duration ECMO [hours] | 312.34 (208.30; 479.50) | 70.78–1068.31 | 253.80 (163.27; 347.93) | 16.78–577.63 | |
| Cytosorb | 0 | 8 (8.5%) | < 0.05 | ||
| Duration Cytosorb [hours] | 20.00 (17.17; 21.15) | 8.67–51.00 | |||
| Red Cell Transfusion | 5 (1; 8) | 1–36 | 7 (3; 13) | 1–40 | |
| NO inhalation | 12 (13.3%) | 50 (53.2%) | < 0.05 | ||
| Corticosteroid | 73 (81.1%) | 92 (97.9% | < 0.05 | ||
| Immunoglobulin | 2 (2.2%) | 2 (2.1%) | |||
| Convalescent plasma | 20 (22.2%) | 14 (14.9%) | |||
| Remdesivir | 14 (15.6%) | 6 (6.4%) | < 0.05 | ||
| Anticoagulation | 90 (100%) | 94 (100%) | |||
| Argatroban at any time on ICU | 8 (8.9%) | 7 (7.4%) | < 0.05 | ||
| UFH at any time on ICU | 51 (56.7%) | 89 (94.7%) | < 0.05 | ||
| LMWH at any time on ICU | 72 (80.0%) | 43 (45.7%) | < 0.05 | ||
| Bacteremia | 36 (40.0%) | 56 (59.6%) | < 0.05 | ||
| Staph. aureus bacteremia | 3 (3.3%) | 9 (9.6%) | |||
| Catheter associated bacteremia | 12 (13.3%) | 12 (12.8%) | |||
| Antibiotics | 84 (93.3%) | 92 (97.9%) | |||
| Antimycotics | 12 (13.3%) | 16 (17.0%) | |||
| CRP maximum value [mg/l] | 229.9 (144.4; 302.2) | 31.4–584.7 | 305.5 (231.2; 373.5) | 81.8–618.0 | < 0.05 |
| Interleukin 6 maximum value [pg/mL] | 152.0 (80.5; 398.0) | 8.6–21,728.0 | 674 (254; 2345) | 15.9–792,732.0 | < 0.05 |
| Leucocytes maximum value [GPt/L] | 17.19 (13.11; 22.43) | 7.06–63.87 | 20.82 (16.75; 27.17) | 3.14–63.64 | < 0.05 |
| Leucocytes minimum value [GPt/L] | 7.22 (5.00; 9.39) | 0.51–15.84 | 7.20 (4.63; 9.74) | 0.20–22.47 | |
| Procalcitonin [ng/ml] | 1.31 (0.43; 6.02) | 0.09–373.20 | 7.39 (2.20; 15.60) | 0.15–148.40 | < 0.05 |
| Prothrombin fragment F1 + 2 [pmol/l] | 393 (231; 780) | 98.0–4948 | 541 (339; 1001) | 73–4948 | |
| Platelets maximum value [GPt/L] | 355 (284; 461) | 103–989 | 286 (219; 357) | 48–617 | < 0.05 |
| Platelets minimum value [GPt/L] | 170 (110; 219) | 4–469 | 96 (47; 139) | 1–414 | < 0.05 |
Data are median (Interquartile range) or n (%).
Significant values are in [bold].
ICU Intensive care unit, ARDS Acute respiratory distress syndrome, Pmean Mean pressure, PEEP Positive end-expiratory pressure, PaCO2 partial pressure of carbon dioxide, SpO2 Oxygen saturation, SOFA Sequential organ failure assessment, CRRT Continuous renal replacement therapy, NO Nitric oxide, UFH Unfractionated heparin, LMWH Low-molecular-weight heparin, Staph. Staphylococcus, CRP C-reactive protein, ECMO extracorporeal membrane oxygenation.